Physician profile
Jared Hostetler
NPI 1386164929
$1,685.88
in general payments reported to CMS, 2019-2025
15 companies · $820 in 2025
The $820 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $170 · 2024: $696 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,685.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $471.24 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $240.16 | 2023-2025 | |
| Novo Nordisk INC | $203.67 | 2024-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $132.05 | 2023-2024 | |
| Lilly USA, LLC | $128.53 | 2023-2025 | Jardiance, Mounjaro |
| Alkermes, INC. | $110.34 | 2025 | Vivitrol |
| Phathom Pharmaceuticals, INC. | $86.94 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.59 | 2024 | Xifaxan |
| Exact Sciences Corporation | $67.44 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.47 | 2024-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $33.22 | 2023-2024 | Gvoke Hypopen |
| Amgen INC. | $30.80 | 2024 | Prolia, Evenity |
| Daiichi Sankyo INC. | $21.08 | 2025 | Injectafer |
| Pfizer INC. | $19.42 | 2024 | |
| Optinose US, INC. | $17.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Hostetler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.